Table 1 Clinicopathologic characteristics of patient groups in TCGA cohort.
From: YAP Activity is Not Associated with Survival of Uveal Melanoma Patients and Cell Lines
| Â | YAP mRNA expression level | P-value | YAP Signature Score (GSVA) | P-value | ||
|---|---|---|---|---|---|---|
Low YAP expression | High YAP expression | Low YAP signature | High YAP signature | |||
Number of Patients | 40 | 40 | — | 40 | 40 | — |
Age, years, Mean (SD) | 63.0 (15.0) | 61.4 (13.1) | 0.62 | 64.9 (13.2) | 59.5 (14.4) | 0.09 |
Male, No. (%) | 23 (57.5%) | 22 (55%) | 0.99 | 22 (55%) | 23 (57.5%) | 0.99 |
Basal diameter (mm)* | 16.3 ± 3.8 | 16.8 ± 3.8 | 0.72 | 15.9 ± 3.7 | 17.2 ± 3.9 | 0.13 |
Thickness (mm)* | 10.3 ± 2.7 | 10.5 ± 2.9 | 0.7 | 10.3 ± 2.6 | 10.5 ± 3.0 | 0.79 |
AJCC stage (8th edition) | ||||||
   Stage IIA, No. (%) | 3 (7.5%) | 1 (2.5%) | 0.9 | 3 (7.5%) | 1 (2.5%) | 0.6 |
   Stage IIB, No. (%) | 17 (42.5%) | 15 (37.5%) |  | 17 (42.5%) | 15 (37.5%) |  |
   Stage IIIA, No. (%) | 12 (30%) | 15 (37.5%) |  | 10 (25%) | 17 (42.5%) |  |
   Stage IIIB, No. (%) | 5 (12.5%) | 5 (12.5%) |  | 6 (15%) | 4 (10%) |  |
   Stage IIIC, No. (%) | 1 (2.5%) | 2 (5%) |  | 2 (5%) | 1 (2.5%) |  |
   Stage IV, No. (%) | 2 (5%) | 2 (5%) |  | 2 (5%) | 2 (5%) |  |
Dominant cell types | ||||||
   Spindle, No. (%) | 34 (85%) | 23 (57.5%) | 0.013 | 33 (82.5%) | 24 (60%) | 0.047 |
   Epithelioid, No. (%) | 6 (15%) | 17 (42.5%) |  | 7 (17.5%) | 16 (40%) |  |
Pigmentation | ||||||
   Minimal, No. (%) | 14 (35%) | 25 (62.5%) | 0.025 | 19 (47.5%) | 20 (50%) | 0.99 |
   Marked, No. (%) | 26 (65%) | 15 (37.5%) |  | 21 (52.5%) | 20 (50%) |  |
Mitotic count | ||||||
   0-5/HPF, No. (%) | 32 (80%) | 31 (77.5%) | 0.84 | 34 (85%) | 29 (72.5%) | 0.42 |
   5-10/HPF, No. (%) | 6 (15%) | 5 (12.5%) |  | 4 (10%) | 7 (17.5%) |  |
   >11/HPF, No. (%) | 2 (5%) | 4 (10%) |  | 2 (5%) | 4 (10%) |  |
GNAQ/11 mutation, No. (%) | 37 (92.5%) | 36 (90%) | 0.99 | 38 (95%) | 35 (87.5%) | 0.43 |
BAP1 mutation, No. (%) | 13 (32.5%) | 22 (55%) | 0.07 | 13 (32.5%) | 22 (55%) | 0.07 |
EIF1AX mutation, No. (%) | 6 (15%) | 4 (10%) | 0.74 | 6 (15%) | 4 (10%) | 0.74 |
SF3B1 mutation, No. (%) | 11 (27.5%) | 7 (17.5%) | 0.42 | 13 (32.5%) | 5 (12.5%) | 0.06 |
